{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:09:47Z","timestamp":1777936187893,"version":"3.51.4"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.2169\/internalmedicine.5874-25","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:08:20Z","timestamp":1758146900000},"page":"1205-1209","source":"Crossref","is-referenced-by-count":0,"title":["Administration of Nivolumab Plus FOLFOX Therapy to a Patient with Gastric Cancer Undergoing Hemodialysis"],"prefix":"10.2169","volume":"65","author":[{"given":"Taichi","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoaki","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"},{"name":"Department of Medical Oncology, Akita Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shimazu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Graduate School of Medicine, Akita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hanafusa N, Abe M, Hoshino J, et al.; Japanese Society for Dialysis Therapy Renal Data Registry Committee. Annual dialysis data report 2020, JSDT renal data registry. Ren Replace Ther 10: 14, 2024.","DOI":"10.1186\/s41100-024-00531-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.","DOI":"10.3322\/caac.21660"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y. Treatment of gastric and gastroesophageal cancer patients with hemodialysis by CapeOX. Intern Med 58: 2791-2795, 2019.","DOI":"10.2169\/internalmedicine.2718-19"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maruta M, Miyoshi T, Matsuo N, et al. Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. J Chemother 33: 51-55, 2021.","DOI":"10.1080\/1120009X.2020.1728861"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-esophageal junction cancer (ATTRACTION-4): a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23: 234-247, 2022.","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-esophageal junction, and esophageal adenocarcinoma (CheckMate 649): a randomized, open-label, phase 3 trial. Lancet 398: 27-40, 2021.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 26: 1-25, 2023.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Marte G, Tufo A, Steccanella F, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systematic review of the literature and meta-analysis of prognostic factors. J Clin Med 10: 1141, 2021.","DOI":"10.3390\/jcm10051141"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takahashi K, Terashima M, Notsu A, et al. Surgical treatment for liver metastasis from gastric cancer: a systematic review and meta-analysis of long-term outcomes and prognostic factors. Eur J Surg Oncol 50: 108582, 2024.","DOI":"10.1016\/j.ejso.2024.108582"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Shirasu H, Tsushima T, Kawahira M, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer 21: 338-344, 2018.","DOI":"10.1007\/s10120-017-0730-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: result of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24: 501-507, 2013.","DOI":"10.1093\/annonc\/mds344"},{"key":"12","doi-asserted-by":"crossref","first-page":"e000301","DOI":"10.1136\/esmoopen-2017-000301","volume":"23","author":"T Funakoshi","year":"2018","unstructured":"12. Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 23: e000301, 2018.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ishii T, Watanabe T, Higashi T. Differences in the performance of adjuvant chemotherapy between hemodialysis and nonhemodialysis patients. Cancer Med 12: 4033-4041, 2022.","DOI":"10.1002\/cam4.5258"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cheun H, Kim M, Lee H, Oh KH, Keam B. Safety and efficacy of immunocheckpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs 37: 579-583, 2019.","DOI":"10.1007\/s10637-018-0673-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Klajer E, Garnier L, Goujon M, et al. Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systematic review. Semin Oncol 47: 103-116, 2020.","DOI":"10.1053\/j.seminoncol.2020.05.001"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant <i>DPYD<\/i> alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10: 217-223, 2000.","DOI":"10.1097\/00008571-200004000-00002"},{"key":"17","unstructured":"17. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishikawa Y, Funakoshi T, Horimatsu T, et al. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79: 629-633, 2017.","DOI":"10.1007\/s00280-017-3249-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Imamaki H, Oura M, Oguro F, et al. Removal rate of 5-fluorouracil and its metabolites in patients on hemodialysis: a report of two colorectal cancer patients with end-stage renal failure. Cancer Chemother Pharmacol 93: 161-167, 2024.","DOI":"10.1007\/s00280-023-04577-w"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chaudhuri NK, Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines: VII - the degradative pathway. Biochem Phalmacol 1: 328-341, 1959.","DOI":"10.1016\/0006-2952(59)90121-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21: 1395-1403, 2010.","DOI":"10.1093\/annonc\/mdp598"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wang D, Li X, Xu L, et al. Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: a case report. Medicine (Baltimore) 94: e17462, 2019.","DOI":"10.1097\/MD.0000000000017462"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68: 263-266, 2011.","DOI":"10.1007\/s00280-011-1633-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kim JS, Kio KU, Henderson H, Pourshahid S. A case of acute encephalopathy after the initiation of FOLFOX chemotherapy in a patient with colon cancer. Cureus 15: e37237, 2023.","DOI":"10.7759\/cureus.37237"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. Jpn J Clin Oncol 40: 360-364, 2010.","DOI":"10.1093\/jjco\/hyp176"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nagatani Y, Imamura Y, Nakamura T, et al. Pharmacokinetics of oxaliplatin in a hemodialysis patient with metastatic colon cancer. Int J Oncol Res 2: 017, 2019.","DOI":"10.23937\/2643-4563\/1710017"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gori S, Lunardi G, Inno A, et al. Pharmacokinetics of oxaliplatin in a hemodialysis patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer 13: 260-263, 2014.","DOI":"10.1016\/j.clcc.2014.09.003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nakata B, Chung KH, Kato Y, et al. Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83: 2488-2492, 1998.","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2488::AID-CNCR12>3.0.CO;2-1"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 15: 154-161, 2012.","DOI":"10.1007\/s10120-011-0091-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hwang GI, Yoo CH, Sohn BH, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat 36: 178-181, 2004.","DOI":"10.4143\/crt.2004.36.3.178"},{"key":"32","unstructured":"32. Hasegawa H, Fujitani K, Nakazuru S, et al. Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom\/tumor marker-based versus CT-based. Anticancer Res 34: 5169-5174, 2014."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/9\/65_5874-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:22:14Z","timestamp":1777692134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/9\/65_5874-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5874-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"5874-25"}}